Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart C Gordon

Showing results (211-220 of 214) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 214 results.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
JHEP Reports : Innovation in Hepatology|July 18, 2024
The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver diseaseZobair M Younossi, Saleh A AlQahtani, Jesús Funuyet-Salas, et al.
Pageof 22

Showing results (211-220 of 214) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 214 results.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
JHEP Reports : Innovation in Hepatology|July 18, 2024
The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver diseaseZobair M Younossi, Saleh A AlQahtani, Jesús Funuyet-Salas, et al.
Pageof 22